70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial-Reference-Cited by-同舟云学术

70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

Published:2011-07 Issue:4 Volume:80 Page:1056-1063
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Beckendorf Véronique,Guerif Stéphane,Le Prisé Elisabeth,Cosset Jean-Marc,Bougnoux Agnes,Chauvet Bruno,Salem Naji,Chapet Olivier,Bourdain Sylvain,Bachaud Jean-Marc,Maingon Philippe,Hannoun-Levi Jean-Michel,Malissard Luc,Simon Jean-Marc,Pommier Pascal,Hay Men,Dubray Bernard,Lagrange Jean-Léon,Luporsi Elisabeth,Bey Pierre

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference40 articles.

1. Prostate cancer and radiation therapy—The message conveyed by serum prostate-specific antigen;Zagars;Int J Radiat Oncol Biol Phys,1995

2. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome;Zietman;Int J Radiat Oncol Biol Phys,1995

3. The effect of dose on local control of prostate cancer;Hanks;Int J Radiat Oncol Biol Phys,1988

4. External beam radiotherapy dose response of prostate cancer;Pollack;Int J Radiat Oncol Biol Phys,1997

5. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer;Zelefsky;Int J Radiat Oncol Biol Phys,1998

Cited by 381 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy;Radiation Oncology;2024-09-02

2. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-09

3. Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec–led Phase 3 Trial;European Urology;2024-09

4. Volumetric Modulated Arc Therapy for High-Risk and Very High-Risk Locoregional Prostate Cancer in the Modern Era: Real-World Experience from an Asian Cohort;Cancers;2024-08-25

5. Long-term evaluation of the safety of a rectal-prostate spacer, the ProSpace® balloon, in patients treated with radiotherapy for prostate cancer;BMC Cancer;2024-08-01